Table 1.
Demographic characteristics of patients with SCI/MCI or AD at baseline
| SCI/MCI(n = 106) | AD(n = 59) | p | |
| Age (y) | 64.0 (59.5–71) | 69.0 (62.0–75.0) | <0.01 |
| Gender, n (%) | 0.05 | ||
| Male | 34 (32) | 28 (47) | |
| Female | 72 (68) | 31 (53) | |
| BMI (kg/m2) | 24.7 (22.2–27.0) | 24.2 (21.8–26.0) | 0.24 |
| Serum HDL (mmol/L) | 1.8 (1.4–2.2) | 1.8 (1.6–2.1) | 0.84 |
| Serum LDL (mmol/L) | 3.3 (2.9–3.9) | 3.4 (2.7–4.0) | 0.86 |
| LDL/HDL ratio | 1.9 (1.4–2.5) | 1.7 (1.4–2.4) | 0.59 |
| Diastolic blood pressure (mmHg) | 79 (74–86) | 80 (74–85) | 0.70 |
| Systolic blood pressure (mmHg) | 139 (125–151) | 150 (132–165) | <0.01 |
| MAP (mmHg) | 99 (92–107) | 103 (96–109) | 0.045 |
| Education (y) | 14 (11–16) | 13 (9–15) | 0.17 |
| Smoking, n (%) | |||
| Never | 61 (57) | 35 (60) | 0.77 |
| Previous | 7 (7) | 5 (9) | |
| Current | 38 (36) | 18 (31) | |
| Hypertension, n (%) | |||
| Yes | 36 (36) | 34 (59) | <0.01 |
| No | 64 (64) | 24 (41) | |
| Serum IGF-I (ng/mL) | 113 (95–139) | 118 (95–146) | 0.44 |
| CSF/serum albumin ratio | 5.4 (4.3–6.9) | 5.8 (4.8–8.7) | 0.06 |
| CSF Aβ1–42 (ng/L) | 580 (456–790) | 357 (256–463) | <0.001 |
| CSF T-tau (ng/L) | 331 (210–470) | 530 (323–743) | <0.001 |
| CSF P-tau (ng/L) | 49 (38–67) | 77 (60–95) | <0.001 |
| APOE ɛ4, n (%) | |||
| 0 | 50 (51) | 17 (30) | 0.02 |
| 1 | 40 (41) | 28 (50) | |
| 2 | 8 (8) | 11 (20) |
Values are presented as the median (25th–75th percentiles) if not stated otherwise. Between-group differences were calculated using Mann-Whitney U tests for continuous variables and chi-square tests for categorical variables. Significant p values are given as bold text. APOE genotyping was not performed in 11 patients. Aβ1 - 42, amyloid β amino acids 1 to 42; AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body mass index; CSF, cerebrospinal fluid; IGF-I, insulin-like growth factor-I; HDL, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol; MAP, mean arterial pressure; MMSE, Mini Mental State Examination; P-tau, phosphorylated tau; SCI/MCI, subjective/objective mild cognitive impairment; T-tau, total tau.